US 12,280,076 B2
Use of Rhodococcus ruber cell wall skeleton in regenerative medicine
Bo Gai, Benxi (CN); Chunyan Dou, Benxi (CN); Peisheng Jin, Benxi (CN); Yi Zhang, Benxi (CN); and Guoying Zhang, Benxi (CN)
Assigned to LIAONING GREATEST BIO-PHARMACEUTICAL CO., LTD., Benxi (CN)
Appl. No. 17/792,396
Filed by LIAONING GREATEST BIO-PHARMACEUTICAL CO., LTD., Benxi (CN)
PCT Filed Jan. 20, 2021, PCT No. PCT/CN2021/072871
§ 371(c)(1), (2) Date Jul. 12, 2022,
PCT Pub. No. WO2021/147899, PCT Pub. Date Jul. 29, 2021.
Claims priority of application No. 202010068249.1 (CN), filed on Jan. 21, 2020.
Prior Publication US 2023/0069441 A1, Mar. 2, 2023
Int. Cl. A61K 35/28 (2015.01); A61K 35/545 (2015.01); A61K 35/74 (2015.01); A61P 17/02 (2006.01); C12N 1/20 (2006.01); C12R 1/01 (2006.01)
CPC A61K 35/28 (2013.01) [A61K 35/545 (2013.01); A61K 35/74 (2013.01); A61P 17/02 (2018.01); C12N 1/205 (2021.05); C12R 2001/01 (2021.05)] 17 Claims
 
1. A method of regulating mesenchymal stem cells comprising exposing the stem cells to a product derived from Rhodococcus ruber cell wall; wherein the ratio of the number of stem cells to the product derived from Rhodococcus ruber cell wall is 1 to 100 stem cells per 1 ng of the product derived from Rhodococcus ruber cell wall.